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Malignant pleural effusion; Lung carcinoma; Hyperthermic perfusion chemotherapy Summary Objectives: Malignant pleural effusion (MPE) means poor prognosis in the majority of cases. Intrapleural Hyperthermic perfusion chemotherapy (HIPEC) looks promising approach for these patients. We aimed to investigate whether cytoreductive surgery followed by HIPEC provides any survival benefit in cases with metastatic MPEs. Methods: Between January 2009 and December 2011, 19 patients with metastatic MPEs were treated with HIPEC following surgical interventions such as pleurectomy/decortication and/ or lung resection (Group 1). Comparison was done with historical control groups consisted of patients who received either talc pleurodesis or pleurectomy/decortication followed by systemic treatment for the management of metastatic MPEs between June 2007 and June 2008 (group 2 and 3). Statistical analyses including overall survival, disease free interval were done for the group comparisons. Results: Median survival in group 1, 2 and 3 were 15.4, 6, 8 months, respectively. One year survival was 54.7% in group 1 where it was 0.6% and 0.8% in group 2 and 3, respectively. There was no operative mortality. Morbidity was occurred in 1 patient in group 1 (5.3%). Conclusions: HIPEC combined with cytoreductive surgery seems to be a promising treatment option for subjects with metastatic MPEs. Further studies are needed for the optimization of HIPEC method, drug of choice, and the best combination therapy for the multimodal treatment. ª 2013 Elsevier Ltd. All rights reserved.
Introduction
Malignant pleural effusion (MPE) is not a rare entity faced by pulmonary clinicians and thoracic surgeons.
1,2 The metastatic malignancies of pleura are more common than its primary tumors. Lung cancer is the most common primary neoplasm metastasizes to pleura followed by breast cancer and lymphoma. 3 Current treatment options of malignant pleural effusions are limited to supportive care in the majority of patients. MPE related to lung carcinoma means a median survival of 4e6 months despite using multimodal treatments including surgery, chemotherapy and radiotherapy. 4 Therefore, new therapeutic options are needed. It has been suggested by Giovanella and colleagues that hyperthermia itself is tumoricidal. 5 Exposure to temperatures of 42.5e43
C for 4e8 h has been shown to have significantly greater lethal effect on the tumor cells compared to non-neoplastic cells in cell culture models. It has also been shown that hyperthermia increase the cytotoxicity of many chemotherapeutic agents in human cell culture models and animal models. 6, 7 Spratt and colleagues pioneered a system to deliver hyperthermic chemotherapy to the peritoneal cavity in a canine model and in human in 1980. 8 This was followed by several studies using similar systems to perform hyperthermic perfusion chemotherapy (HIPEC) to the peritoneal cavity in subjects with abdominal cancers including malignant peritoneal mesothelioma.
9e11 These studies reported significant survival advantage of intraperitoneal HIPEC compared to standard of care. These optimistic results lead researchers to investigate whether intrapleural (IP) HIPEC works in subjects with malignant pleural effusion. Although there are limited data, IP HIPEC in malignant pleural effusions looks promising. 12, 13 In this study, we aimed to investigate the survival and disease free interval in subjects with metastatic pleural malignancies who underwent IP HIPEC in addition to cytoreduction.
Materials and methods
The hospital records of the subjects with malignant pleural effusion who admitted to Department of Thoracic Surgery of Gaziantep University Hospital between January 2009 and December 2011 were reviewed in a retrospective manner. The patients who underwent IP HIPEC in addition to cytoreduction for the management of metastatic MPE were included in group 1. Another two groups of patients with secondary MPE who have been investigated in our previous study were included as the historical control groups and defined as group 2 and 3.
14 Subjects in group 2 received talc pleurodesis and subjects in group 3 received pleurectomy/decortication by video assisted thoracic surgery (VATS) for the management of metastatic MPE. All of the subjects in groups received systemic chemotherapy following pleural interventions. Selection criteria were as follows: subjects with metastatic pleural malignancies proved by pleural cytology and/or biopsy, subjects with good performance status, subjects with lung cancer and no distant metastasis except pleura, subjects with lung cancer and nodal status of N1 or less. Informed consent forms were signed by all subjects. The study protocol was approved by institutional Ethics Committee.
Overall survival defined as the period from the date of the first therapeutic intervention as cytoreduction plus HIPEC and pleurodesis to the date of death. Disease free interval was accepted as recurrence of malignant pleural effusion proved by cytological or histopathological examination.
Cytoreduction in group 1 was performed as pleurectomy and decortication in all subjects. Additionally lung and adjacent structures were resected if possible. Parietal, mediastinal and diaphragmatic pleura were resected. Only in one patient, diaphragma had to be resected in order to provide maximum cytoreduction. Large bore (28e32 F) chest tubes were inserted at the end of surgery before the thoracic cavity was closed. HIPEC was performed through these chest tubes. HIPEC was applied intraoperatively using a perfusator (Rand Performer LRT-Medolla/Italy). The temperature was set to 42 C, and the intrapleural perfusion was first started with 0.9% sodium chloride isotonic solution. During the IP lavage, the effected lung was allowed to be half inflated and the lavage was continued until perfusate (0.9% sodium chloride isotonic solution) comes from the exit tube. The volume of saline used was ranged between 1500 and 3200 mL with 1e1.2 L/min flow rate. This stage took about 1 h. Then IP HIPEC was performed by using 300 mg/m 2 of Cisplatin for 60 min. In order to protect brain from the side effects of hyperthermia, ice bags were placed around patient's head during intrapleural perfusion. Hydration with 50 mL/kg/24 h saline, dextrose solution and fresh frozen plasma was performed in all subjects in order to prevent renal complications in the postoperative 24 h. Oral intake was begun on the first postoperative day.
Selection criteria were as follows: subjects with metastatic pleural malignancies proved by pleural cytology and/ or biopsy, subjects with good performance status, subjects with lung cancer and no distant metastasis except pleura, subjects with lung cancer and nodal status of N1 or less. All subjects over 20 years old diagnosed to have metastatic MPE during the study period were included. Malignant pleural effusion was defined as exudative pleural effusion associated with one of the followings: positive cytology/histopathology for malignancy, known primary cancer without co morbid conditions which may cause exudative pleural effusion.
Talc pleurodesis was performed through a small bore chest tube (Pleurocan, B. Brown, Melsungen, Germany) in the form of slurry (4.5 g talc in/100 ml saline solution).
VATS pleurectomy was performed as follows: all apical and basal parts of parietal pleura were excised except mediastinal and diaphragmatic sides under general anesthesia.
All subjects in groups received systemic chemotherapy planned according to primary cancer. The systemic chemotherapy protocols were cisplatin based in all subjects. Interventional, histopathological data and chemotherapy protocols were given in Table 1 .
Statistical analysis
The KaplaneMeier method was used to estimate the survival curve. Log rank (Mantel-cox) was used for comparison of groups. SPSS version 17 (SPSS Science, Chicago, Illinois) was used for the statistical calculations. p < 0.05 was accepted as significant in group comparisons.
Results
Group 1 included 19 patients with mean age of 53.4 (14 male and five female). Group 2 included 13 subjects with mean age of 54.3 (6 male and 7 female). Group 3 included 12 subjects with mean age of 55.6 (7 male and 5 female).
A total of 21 surgical interventions were performed in 19 patients (Table 1) . Two patients needed second resection (completion pneumonectomy and wedge resection) due to recurrences. Overall, two lobectomies, three pneumonectomies and 16 pleurectomy/decortication were performed. The primary origins of tumors in treatment groups were shown in Table 2 .
Median survival in group 1, 2 and 3 were 15, 6, and 8 months respectively (Fig. 1) . One year survival was 54.7% in group 1 while it was 0.6% and 0.8% in group 2 and in group 3, respectively (p < 0.01 and p < 0.05). Overall survival was not different between group 2 and group 3. The subgroup analysis for the comparison of survival between cases with primary lung carcinoma in treatment groups showed that overall survival was significantly longer in those cases in group 1 (p < 0.05) (Fig. 2) . On the other hand, seven out of 19 patients had MPE with primary tumor other than lung carcinoma. Primary tumors in these cases were as follows: malignant mesenchymal tumors in four cases, digestive canal tumors in two cases, and malignant thymoma in one patient. Twelve and 15 months survival in this subgroup was found to be 57.1% and 42.9%, respectively. Two patients died in this subgroup and both of them were malignant mesenchymal tumors.
No intraoperative mortality was experienced in group 1. Specific complication due to IP HIPEC was occurred in one 
Malign Epitelial Tm (Large cell Neuroendocrine Carcinom) (LC)
Malign Fibrouse Histiocitoma (Right gluteal muscle)
Malign Mesenchyimal Tm (Secondary to radiotherapy after operated Breast CA.) 
Discussion
This study shows that IP HIPEC in combination with cytoreduction provides significantly better survival compared to those who received either pleurectomy or talc pleurodesis for the management of metastatic pleural malignancies. Intrathoracic space is covered by a serous membrane, called pleura, and plays a preventing role for disease expansion from one side to other. Nearly all malignant tumors (solid tumors and hematologic malignancies) may spread to the pleural surface. 15 Either primary or metastatic pleural cancers have bad prognosis and short survival expectation so that there is no standard approach for treatment. 4 Median survival following diagnosis ranges from 3 to 12 months and is depended on the stage and the type of the underlying malignancy. 16 Survival in MPE is the shortest in subjects with primary lung cancer while it was the longest in subjects with primary ovarian cancer. Currently, palliative therapy either with pleurodesis or pleurectomy/ decortication is the choice of treatment in secondary MPEs. 17 Other treatment approaches are chemotherapy and/or radiotherapy. Unfortunately, none of these approaches provides a significant benefit for the survival. In the present study median survival was found to be 15.6 months in group 1 (HIPEC group) where it was 6 months in group 2 (talc group) and 8 months in group 3 (pleurectomy group). One year survival was found to be 54.7% in group 1 compared to 0.6% in group 2 and 0.8% in group 3.
MPE associated with primary lung carcinoma has the worst survival. There are few studies in English literature reported the results of IP HIPEC in MPEs associated with primary lung carcinoma.
12,18,19 Shigemura et al. 12 used IP HIPEC through thoracoscope before pleuropneumonectomy in 5 non-small cell lung cancer patients with pleural involvement. Thoracotomy for pleuropneumonectomy was performed immediately flowing IP HIPEC for each subject. They reported mean survival of 19 months. They also stressed that four patients were still alive when the article was published and the longest survival was 32 months. Kodoma et al. 18 applied IP HIPEC in 26 cases of lung carcinoma with pleural involvement 10e14 days after pulmonary resection and reported 5 year cumulative survival of 24.6%. Twenty-four of these patients had an initial diagnosis of pleural involvement at thoracotomy. The other seven patients had massive malignant effusion at the time of the initial diagnosis. Local relapse free survival was found as 76.3%. Additionally, negative mediastinal lymph node involvement revealed much longer survival. Three and 5 year survival were as 68.4% and 42.7%, respectively. However, even if in the patients with mediastinal lymph node Figure 1 Survival probability of subjects in groups (1: HIPEC group; 2 and 3: Talk pleurodesis and VATS pleurectomy groups respectively) (p < 0.01 and p < 0.05). Figure 2 Intergroup comparison of survival between subjects with lung cancer (1: Lung cancer in HIPEC group; 2: Lung cancer in groups 2 and 3): The survival was significantly longer in subjects with lung cancer in group 1 compared to group 2 and group 3 (p < 0.05). involvement, they found 3 year survival rate as 22.7%. According to us, these results show support the benefit of the hyperthermic perfusion after surgical interventions. Matsuzaki et al. 19 reported median survival of 20 months in subjects who received pulmonary resection followed by IP HIPEC compared to six months in subjects who received only pulmonary resection for the treatment of lung cancer with pleural involvement, although, the difference in survival was not statistically significant between two groups. In the present study, there were twelve cases of primary lung carcinoma with MPEs. Among these cases, 6 died and 6 cases were still alive during the writing process of this article. The survival time for these 6 patients was ranged between seven and 30 months. Although, there are methodological differences in these studies the IP HIPEC treatment looks promising in pulmonary carcinoma with pleural involvement.
There are limited data on the effects of IP HIPEC in metastatic MPEs associated with primary cancers other than lung carcinoma. Refaely et al. 20 reported the results of IP HIPEC on 15 subjects of thymic malignancies with pleural spread. They performed IP HIPEC in all subjects while they performed resection without pleurectomy in 9 patients, resection with pleurectomy in 5 patients, and extrapleural pneumonectomy in 1 patient. They reported survival of 7e70 months in these subjects. They concluded that IP HIPEC along with cytoreduction seems to offer excellent local control for patients with stage IV-a thymic malignancies and may lengthen survival in stage IVa thymoma. In the present study, seven out of 19 patients had MPE with primary tumor other than lung carcinoma. Twelve and 15 months survival were 57.1% and 42.9%, respectively.
The cisplatin is one of the most preferred agents for IP HIPEC due to its direct cytotoxic activity. 21 Cisplatin dosage during IP HIPEC was ranged between 50 mg/m 2 and 400 mg/ m 2 in various studies. 12,19,21e26 Several toxic side effects related to intrapleural cisplatin dose have been reported by previous studies. Nephrotoxicity is the major concern to prevent using high dose of cisplatin during IP HIPEC. However, increase in dosage of cisplatin gets longer survival time in patients. Richards et al. studied the dosage cisplatin between 50 and 250 mg/m 2 and found that patients treated with 250 mg/m 2 cisplatin had much longer survival time. 25 For this reason we preferred to apply 300 mg/m 2 of IP cisplatin to all subjects. Only one patient had a moderate increase in urea and creatinine levels and it was successfully managed by intravenous fluid treatment without any complication.
There are certain limitations to this study. First of all this is a retrospective study with low number of subjects. Secondly, the historical control groups used for the comparison of survival in different groups. Finally, there was no homogeneity in the origins of primary tumors in the groups.
In conclusion, cytoreduction followed by IP HIPEC looks promising to provide better survival compared to talc pleurodesis or pleurectomy/decortication in the management of metastatic MPEs. Larger studies needed for the optimization of IP HIPEC method, the dosage and the type of chemotherapeutic agent and the best combination therapies in addition to IP HIPEC.
